OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Oncolytics is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Ferroptosis gene signature in cholangiocarcinoma	83
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	56
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	55
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	48
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	40
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	37
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	37
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	36
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	36
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	35
PROTACs in gastrointestinal cancers	35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer	34
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T	31
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme	30
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy	30
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia	29
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges	28
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	27
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia	27
Radiovirotherapy at twenty	26
Adding recombinant AAVs to the cancer therapeutics mix	26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products	25
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice	24
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum	24

ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma	24
Oncolytic adenovirus for treatment of malignant ascites	24